News from the FDA/CDC

Sleep issues vary by menopausal status

Publish date: September 12, 2017
By
Richard Franki

 

Perimenopausal women aged 40-59 years were less likely than were others in the same age group to average at least 7 hours’ sleep each night in 2015, according to the National Center for Health Statistics.

Among the perimenopausal women in that age group, 56% said that they slept less than 7 hours, on average, in a 24-hour period, compared with 40.5% of postmenopausal women and 32.5% of those who were premenopausal. Overall, 35.1% of women aged 40-59 did not average at least 7 hours of sleep per night, the NCHS reported in a data brief released Sept. 7.

Sleep measures by menopausal status in women aged 40-59
Measures of sleep quality, however, tell a different story. Postmenopausal women aged 40-59 were most likely to report that they did not wake up feeling rested on 4 or more days in the past week: 55.1%, versus 49.9% of perimenopausal and 47% of premenopausal women. Postmenopausal women also were the most likely to have trouble falling asleep 4 or more nights in the past week and to have trouble staying asleep 4 or more times in the past week, data from the 2015 National Health Interview Survey show.

For this analysis, about 74% of the women included were premenopausal (still had a menstrual cycle), 4% were perimenopausal (last menstrual cycle was 1 year before or less), and 22% were postmenopausal (no menstrual cycle for more than 1 year or surgical menopause after removal of their ovaries).

Recommended Reading

Postmenopausal hot flashes cut by 93% with novel nonhormonal treatment
MDedge Endocrinology
FDA approves abaloparatide for postmenopausal osteoporosis
MDedge Endocrinology
Updated osteoporosis guideline advocates bisphosphonates, nixes estrogens
MDedge Endocrinology
Endometrial cancer rates increased following WHI
MDedge Endocrinology
USPSTF discourages postmenopausal hormone therapy for prevention
MDedge Endocrinology
Endometriosis after menopause: Weigh the treatment risks
MDedge Endocrinology
Romosozumab cuts new vertebral fracture risk by 73%, but safety data are concerning
MDedge Endocrinology
Anabolic agents for osteoporosis have limited role so far
MDedge Endocrinology
Focus on lifestyle to manage menopause symptoms after breast cancer
MDedge Endocrinology
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
MDedge Endocrinology

Related Articles